The Congressional Budget Office said Monday that a provision in the GOP’s reconciliation bill that widened an exemption for ...
The U.S. Congressional Budget Office said on Monday that new exemptions to drug price negotiations for several blockbuster ...
The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost ...
A provision of the summer’s One Big Beautiful Bill Act bumping a slew of orphan drugs from Medicare price negotiation is ...
The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to ...
The Congressional Budget Office says exemptions for orphan drugs as part of Medicare price negotiations will cost taxpayers ...
An unnamed source clarified that Sandra Retzky has not been fired from the FDA, but it remains unclear where she was ...
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the USOrphan Drug Designation previously granted by the ...
Enrollment for this Phase 3 program follows positive Phase 1/2 data demonstrating that ADX-324 achieved significant and durable suppression of prekallikrein (PKK) protein levels with a favorable ...
The FDA granted orphan drug designation to cintredekin besudotox for glioblastoma, supporting further research for this aggressive brain cancer.
US Rare Disease Drug Sales Market Opportunity To Surpass USD 190 Billion By 2030 Says Kuick ResearchDelhi, Oct. 16, 2025 ...
The Congressional Budget Office has revised its forecast showing the recently enacted One Big Beautiful Bill Act will cost taxpayers as much as $8.8 billion — up from earlier estimates of $4.9 billion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback